Publications by authors named "Jim Ferry"

Claim this Profile
U
Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: A guide for clinicians.
Barry E Gidal, Jim Ferry, Larisa Reyderman, Jesus E Piña-Garza

Epilepsy Behav· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults.
Ishani Landry, Kenya Nakai, Jim Ferry, Jagadeesh Aluri, Nancy Hall

Clin Pharmacol Drug Dev· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in perampanel levels during de-induction: Simulations following carbamazepine discontinuation.
Edgar Schuck, Jim Ferry, Barry Gidal, Ziad Hussein

Acta Neurol Scand· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC Study.
Borje Darpo, Charles Benson, Randy Brown, Corina Dota, Georg Ferber, Jim Ferry

J Clin Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjunctive Perampanel Oral Suspension in Pediatric Patients From ≥2 to <12 Years of Age With Epilepsy: Pharmacokinetics, Safety, Tolerability, and Efficacy.
J Ben Renfroe, Mark Mintz, Ronald Davis, Jose Ferreira, Sharon Dispoto, Jim Ferry

J Child Neurol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential protein-binding displacement interactions with perampanel: An in vitro analysis.
Barry E Gidal, Jim Ferry, Antonio Laurenza, Takashi Ueno

Epilepsy Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
Maiko Nomoto, Jim Ferry, Ziad Hussein

J Clin Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer.
Seiichi Hayato, Robert Shumaker, Jim Ferry, Terri Binder, Corina E Dutcus

Cancer Chemother Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
Maiko Nomoto, Cynthia A Zamora, Edgar Schuck, Peter Boyd, Min-Kun Chang, Jim Ferry

Br J Clin Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.
Maiko Nomoto, Gina Pastino, Bhaskar Rege, Jagadeesh Aluri, Jim Ferry

Clin Pharmacol Drug Dev· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing placebo exposure in trials: Considerations from the Research Roundtable in Epilepsy.
Brandy E Fureman, Daniel Friedman, Michel Baulac, Tracy Glauser, Jonathan Moreno, Jim Ferry

Neurology· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Barry E Gidal, Rama Maganti, Antonio Laurenza, Haichen Yang, David A Verbel, Jim Ferry

Epilepsy Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant.
Patricia J Murphy, Sanae Yasuda, Kenya Nakai, Takashi Yoshinaga, Nancy Hall, Jim Ferry

J Clin Pharmacol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures.
Vicente Villanueva, Oneeb Majid, Charcrin Nabangchang, Haichen Yang, Antonio Laurenza, Jim Ferry

Epilepsy Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release Tablet.
Ronald Christopher, Mike Morgan, Jim Ferry, Bhaskar Rege, Yong Tang

Clin Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials.
Oneeb Majid, Antonio Laurenza, Jim Ferry, Ziad Hussein

Br J Clin Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Haichen Yang, Antonio Laurenza, Betsy Williams, Anna Patten, Ziad Hussein, Jim Ferry

Epilepsy Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies.
Antonio Laurenza, Haichen Yang, Betsy Williams, Sharon Zhou, Jim Ferry

Epilepsy Res· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.
Barry E Gidal, Antonio Laurenza, Ziad Hussein, Haichen Yang, Randi Fain, Jim Ferry

Neurology· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.
Barry E Gidal, Oneeb Majid, Jim Ferry, Ziad Hussein, Haichen Yang

Epilepsy Behav· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects.
Yanke Yu, Veronika Logovinsky, Edgar Schuck, June Kaplow, Min-Kun Chang, Jim Ferry

J Clin Pharmacol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Barry E Gidal, Jim Ferry, Oneeb Majid, Ziad Hussein

Epilepsia· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis